George K. Ng Acquires 87,200 Shares of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Stock

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) CEO George K. Ng acquired 87,200 shares of the stock in a transaction dated Monday, January 27th. The shares were purchased at an average price of $0.80 per share, for a total transaction of $69,760.00. Following the completion of the purchase, the chief executive officer now directly owns 87,200 shares in the company, valued at $69,760. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Processa Pharmaceuticals Trading Up 0.6 %

Shares of PCSA traded up $0.00 on Wednesday, reaching $0.59. The company’s stock had a trading volume of 2,168,887 shares, compared to its average volume of 178,404. The stock has a market capitalization of $1.94 million, a PE ratio of -0.17 and a beta of 0.62. Processa Pharmaceuticals, Inc. has a twelve month low of $0.47 and a twelve month high of $3.31. The firm has a fifty day moving average of $0.93 and a 200-day moving average of $1.24.

Processa Pharmaceuticals (NASDAQ:PCSA) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.03). As a group, equities analysts anticipate that Processa Pharmaceuticals, Inc. will post -4.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Processa Pharmaceuticals in a research note on Thursday, December 5th.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.